Literature DB >> 20954103

Success of Malone's antegrade continence enema (MACE) from the patients' perspective.

S Tiryaki1, O Ergun, A Celik, I Ulman, A Avanoglu.   

Abstract

PURPOSE: Fecal incontinence (FI) is a devastating problem for children. The failure of optimal medical treatment may require further interventions such as appendicocutaneostomy. We report on a patients' perspective of the success of a Malone procedure for FI. PATIENTS AND METHODS: The records of 32 patients who had undergone ACE procedure in the past 9 years were reviewed. Patients and families were contacted, and telephone inquiries were conducted to assess the overall success of the operation. The questionnaire covered the concerns of patients/families about the stoma, functional results and changes in the patients' quality of life (QOL).
RESULTS: The indications for ACE stomas were meningomyelocele in 17 patients, anorectal malformation in 8, Hirschsprung/NID in 3, spinal tumor in 3 and traumatic spinal injury in one. 7 laparoscopic and 25 conventional operations were performed. The vermiform appendix was used in 27 of the patients and a cecal flap was used in 5. The most frequent complication was stenosis of the stoma orifice observed in 14 patients. 8 patients responded to dilatations while 6 patients required minor surgical revision. There were 2 perforations during catheterization, and they required surgical repair of the conduit. 5 patients had mild leakage from the stoma; all 5 were open ACE procedures, and required revision. 25 patients could be reached by phone. 5 of these children stopped using the stoma due to previous perforation in 2 patients and stricture in 1. The remaining 2 stopped using their stomas because "they did not like the idea of it". 16 patients are completely clean. 3 patients have occasional soiling. Only one patient was not satisfied with using the ACE stoma and stated that it did not sufficiently improve her condition. 8 patients complained about the duration of the enema (longer than 1 h); however, 5 of them refuse to use the stoma every day. All patients but one perceived a significant improvement in their QOL. Mean QOL scores before and after the procedure were 5.8 (2-9) and 11.5 (5-14), respectively.
CONCLUSIONS: ACE stomas provide a satisfactory improvement in patients' quality of life. Stoma-related complications are not uncommon. The most common problems are strictures, followed by stoma leakage. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2010        PMID: 20954103     DOI: 10.1055/s-0030-1265156

Source DB:  PubMed          Journal:  Eur J Pediatr Surg        ISSN: 0939-7248            Impact factor:   2.191


  6 in total

1.  Peristeen anal irrigation as a substitute for the MACE procedure in children who are in need of reconstructive bladder surgery.

Authors:  Husain Alenezi; Hamdan Alhazmi; Mahmoud Trbay; Amna Khattab; Khalid Fouda Neel
Journal:  Can Urol Assoc J       Date:  2014 Jan-Feb       Impact factor: 1.862

Review 2.  Current management of fecal incontinence: choosing amongst treatment options to optimize outcomes.

Authors:  Julie Ann M Van Koughnett; Steven D Wexner
Journal:  World J Gastroenterol       Date:  2013-12-28       Impact factor: 5.742

Review 3.  Updates in the management of the overactive bladder in patients with myelomeningocele.

Authors:  Gregory E Dean; Christopher Long
Journal:  Curr Urol Rep       Date:  2011-12       Impact factor: 3.092

Review 4.  Pediatric incidental appendectomy: a systematic review.

Authors:  James M Healy; Lena F Olgun; Adam B Hittelman; Doruk Ozgediz; Michael G Caty
Journal:  Pediatr Surg Int       Date:  2015-11-21       Impact factor: 1.827

5.  Antegrade continence enema (ACE): predictors of outcome in 111 patients.

Authors:  S Basson; A Zani; S McDowell; E Athanasakos; S Cleeve; S Phelps; P Charlesworth
Journal:  Pediatr Surg Int       Date:  2014-10-07       Impact factor: 1.827

Review 6.  Surgical treatment of anorectal malformations.

Authors:  Naomi Iwai; Shigehisa Fumino
Journal:  Surg Today       Date:  2012-11-30       Impact factor: 2.549

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.